Altamira Therapeutics Stock Price, News & Analysis

Altamira Therapeutics Ltd. (historically traded on Nasdaq under the ticker CYTO) is a Bermuda-based company focused on RNA delivery technologies and selected legacy therapeutics. According to company disclosures, Altamira is dedicated to developing and supplying peptide-based nanoparticle platforms for efficient RNA delivery to extrahepatic tissues, while also holding interests in commercial-stage and clinical-stage legacy assets in allergy and inner ear disorders.

Core RNA Delivery Business

Altamira describes its core business as the development and commercialization of RNA delivery technology for targets beyond the liver. Its work centers on two proprietary peptide-based nanoparticle platforms, OligoPhore™ and SemaPhore™, which are designed for the delivery of RNA payloads to extrahepatic tissues. Company materials state that these platforms are used for small interfering RNA (siRNA) and are also suited for mRNA and other RNA modalities, and that they are made available to pharmaceutical or biotechnology partners through out-licensing and collaboration arrangements.

Altamira reports two flagship siRNA development programs that use its delivery technology:

• AM-401 for KRAS-driven cancer, described as a preclinical program beyond in vivo proof of concept.
• AM-411 for rheumatoid arthritis, also described as preclinical and beyond in vivo proof of concept.

The company has indicated that it pursues a contract development and licensing model around these platforms, aiming to license its RNA delivery technology to partners for use in their own RNA drug product development programs. It has also reported collaborations evaluating its platforms for applications such as cardiac regeneration and mRNA vaccines, and has referenced joint projects with external partners in these areas.

Legacy and Associated Assets

In addition to its RNA delivery platforms, Altamira holds and manages several legacy assets:

• A 49% stake (with additional economic rights) in Altamira Medica AG, which the company describes as holding the commercial-stage legacy asset Bentrio®, an over-the-counter nasal spray for allergic rhinitis. Company communications refer to Bentrio as a drug-free, preservative-free nasal spray used for the treatment of allergic rhinitis and, in some jurisdictions, for protection against airborne particles.
• Inner ear therapeutics assets that Altamira states it is in the process of partnering or divesting. These include AM-125, a patented nasal spray for the treatment of acute vestibular syndrome and other vertigo-related conditions, and the intratympanic therapeutics Keyzilen® and Sonsuvi® for tinnitus and hearing loss, which have been described as Phase 3 assets in company information.

The company has reported that it partially divested its Bentrio business by selling a majority stake in Altamira Medica to a private investor, while retaining economic participation through its remaining equity interest and rights to a portion of future licensing income and value appreciation.

Corporate History and Location

Altamira Therapeutics traces its origins to 2003, when it was founded under the name Auris Medical. Over time, it transitioned its focus toward RNA delivery technologies and rebranded as Altamira Therapeutics. The company states that it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. Corporate materials also refer to Altamira Therapeutics Ltd. as the parent company of a group that includes operating subsidiaries in Switzerland and the United States, as well as its associated company Altamira Medica AG.

Altamira’s shares were listed on the Nasdaq Capital Market under the symbol CYTO. In a later announcement, the company reported that a Nasdaq Hearings Panel determined to delist its common shares from Nasdaq due to non-compliance with the minimum bid price rule. The company stated that its shares would transition to trading on the OTCQB marketplace under the ticker symbol CYTOF, with the intention of maintaining continuous trading for shareholders.

Strategic Repositioning

Company disclosures describe a strategic pivot toward RNA delivery as its core activity, with legacy assets in allergy and inner ear therapeutics being partnered or divested. Altamira has characterized this as a move toward a less capital-intensive business model based on contract development and licensing of its RNA delivery platforms. As part of this repositioning, the company has reported steps to simplify its group structure, including transferring certain subsidiaries and merging entities in Switzerland to concentrate operations under Altamira Therapeutics AG in Basel.

Within its RNA delivery focus, Altamira has highlighted ongoing research and development activities around nanoparticle formulation, process development, and the evaluation of nanoparticles for specific siRNA or mRNA payloads. It has also referenced scientific publications by independent research groups that used its SemaPhore platform in preclinical models of cancer and inflammatory disease, presenting these as external evidence of the potential of its delivery technologies.

Business Model and Partnerships

Altamira’s described business approach combines internal development programs with partnering and out-licensing. For RNA delivery, the company reports that it collaborates with biotech and pharma partners to evaluate OligoPhore and SemaPhore for specific indications, with the goal of entering licensing agreements if evaluation results are positive. It has also indicated that its flagship programs AM-401 and AM-411 are intended to be advanced to regulatory milestones and then out-licensed at or after early clinical stages.

For its associated Bentrio business, Altamira Medica has entered into license and distribution agreements with regional partners. Company announcements describe agreements with Nuance Pharma covering China, Hong Kong, Macau, South Korea and additional East and South East Asian countries, and with Pharma Nordic covering Norway, Sweden and Denmark. These agreements relate to the marketing and distribution of Bentrio nasal spray for allergic rhinitis and, where approved, for protection against airborne particles.

Regulatory Filings

As a foreign private issuer, Altamira files reports with the U.S. Securities and Exchange Commission, including Form 20-F annual reports and Form 6-K current reports. A referenced Form 6-K filing notes the incorporation by reference of unaudited condensed consolidated interim financial statements and management’s discussion and analysis into certain registration statements on Form F-3 and Form S-8. These filings provide financial and operational details for investors and are part of the company’s ongoing reporting obligations.

Stock and Trading Status

Historically, Altamira’s common shares traded on the Nasdaq Capital Market under the symbol CYTO. The company later reported that Nasdaq determined to delist the shares due to non-compliance with the minimum bid price requirement. Altamira stated that its shares would be delisted from Nasdaq and are expected to begin trading on the OTCQB marketplace under the ticker CYTOF. The company has indicated that this transition is intended to provide continued trading access for shareholders while it pursues its RNA delivery-focused strategy.

Company Classification

Based on industry classification data provided, Altamira Therapeutics operates within Pharmaceutical Preparation Manufacturing in the broader Manufacturing sector. Its activities span preclinical RNA therapeutics, platform technology development, and associated commercial-stage and clinical-stage assets in allergy and inner ear therapeutics.